A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity | Zendy

Adonis A. Rubio | Zendy; Maria V. Filsinger Interrante | Zendy; Benjamin N. Bell | Zendy; Clayton L. Brown | Zendy; Theodora U. J. Bruun | Zendy; Celia C. LaBranche | Zendy; David C. Montefiori | Zendy; Peter S. Kim | Zendy

Open Access

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity

Author(s) -

Adonis A. Rubio,

Maria V. Filsinger Interrante,

Benjamin N. Bell,

Clayton L. Brown,

Theodora U. J. Bruun,

Celia C. LaBranche,

David C. Montefiori,

Peter S. Kim

Publication year - 2021

Publication title -

journal of virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.617

H-Index - 292

eISSN - 1070-6321

pISSN - 0022-538X

DOI - 10.1128/jvi.02350-20

Subject(s) - gp41 , neutralization , virology , antibody , monoclonal antibody , biology , neutralizing antibody , heptad repeat , enfuvirtide , hiv vaccine , potency , fragment crystallizable region , glycoprotein , lentivirus , microbiology and biotechnology , epitope , human immunodeficiency virus (hiv) , virus , peptide sequence , vaccine trial , immunology , gene , in vitro , genetics , viral disease

Despite advances in antiretroviral therapy, HIV remains a global epidemic and has claimed more than 32 million lives. Accordingly, developing an effective HIV vaccine remains an urgent public health need.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research